Komori
3-D Matrix (7777) · PolicyRestated

Management of the medical products business, including the antibody testing kit business, as a single segment

First written in FY2022-Q1. 1 of 2 entries say "Restated". Latest entry: FY2024-Q3.

2entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022-Q1 – FY2024-Q32021: 120212022: 020222023: 020232024: 12024
Same theme, other companies
Single-segment structure for the Medical Products Business, including antibody test kitsA theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「当社グループは、医療製品事業の単一セグメントのため、記載を省略しております。」

    抗体検査キット等を含む医療製品事業を単一セグメントとして管理・開示する方針を再確認している。
  2. FY2022-Q1First statedAnnual report

    「当連結会計年度より「医療製品事業」の単一セグメントとして管理することが適切と判断しております。」

    前連結会計年度にその他の事業セグメントとして認識していた抗体検査キット販売事業を、経営資源配分・経営管理体制の観点から医療製品事業の単一セグメントに統合する方針を示した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for 3-D Matrix yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Management of the medical products business, including the antibody testing kit business, as a single segment | 3-D Matrix,Ltd. (7777) | Komori